Azvudine for the Treatment of COVID‐19 in Pre‐Existing Cardiovascular Diseases: A Single‐Center, Real‐World Experience

Wu et al., Advanced Science, doi:10.1002/advs.202306050, Mar 2024
Mortality, PSM, COX.. 81% improvement lower risk ← → higher risk Mortality, COX, MV 57% Azvudine for COVID-19  Wu et al.  EARLY TREATMENT Is early treatment with azvudine beneficial for COVID-19? Retrospective 351 patients in China Lower mortality with azvudine (p=0.00084) c19early.org Wu et al., Advanced Science, March 2024 0 0.5 1 1.5 2+ RR
Azvudine for COVID-19
47th treatment shown to reduce risk in January 2023, now with p = 0.000000017 from 39 studies.
No treatment is 100% effective. Protocols combine treatments.
6,200+ studies for 200+ treatments. c19early.org
Retrospective 351 hospitalized COVID-19 patients with pre-existing cardiovascular diseases in China, showing lower mortality with azvudine treatment.
Liver injury. Studies show significantly increased risk of liver injury1,2.
Standard of Care (SOC) for COVID-19 in the study country, China, is average with moderate efficacy for approved treatments3.
risk of death, 81.1% lower, HR 0.19, p < 0.001, treatment 90, control 90, adjusted per study, propensity score matching, multivariable, Cox proportional hazards.
risk of death, 56.9% lower, HR 0.43, p = 0.002, treatment 106, control 245, adjusted per study, multivariable, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wu et al., 27 Mar 2024, retrospective, China, peer-reviewed, 7 authors, average treatment delay 2.0 days. Contact: chenmanhua@zxhospital.com, zhanghongda@fuwai.com.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2025 China United Kingdom Russia USA Sudan Angola Colombia Kenya Mozambique Pakistan Argentina Vietnam Peru Philippines Spain Brazil Italy France Japan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Bosnia-Herzegovina Côte d'Ivoire Eritrea Bulgaria Greece Slovakia Singapore Iceland New Zealand Czechia Mongolia Israel Trinidad and Tobago Hong Kong North Macedonia Belarus Qatar Panama Serbia CAR China favored low-cost treatments.The average efficacy of treatments was moderate.Low-cost treatments improve early treatment, andprovide complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2025 China United Kingdom Russia USA Sudan Angola Colombia Kenya Mozambique Pakistan Argentina Vietnam Peru Philippines Spain Brazil Italy France Japan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Singapore New Zealand Malawi Czechia Mongolia Israel Trinidad and Tobago North Macedonia Belarus Qatar Panama Serbia Syria China favored low-cost treatments.The average efficacy was moderate.Low-cost protocols improve early treatment,and add complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Azvudine for the Treatment of COVID‐19 in Pre‐Existing Cardiovascular Diseases: A Single‐Center, Real‐World Experience
Liu Wu, Zhong‐han He, Ling Huang, Xin Guo, Xu‐yong Li, Hong‐da Zhang, Man‐hua Chen
Advanced Science, doi:10.1002/advs.202306050
COVID-19 can lead to adverse outcomes in patients with pre-existing diseases. Azvudine has been approved for treating COVID-19 in China, but the real-world data is limited. It is aimed to investigate the efficacy of Azvudine in patients with COVID-19 and pre-existing cardiovascular diseases. Patients with confirmed COVID-19 and pre-existing cardiovascular diseases are retrospectively enrolled. The primary outcome is all-cause death during hospitalization. Overall, 351 patients are included, with a median age of 74 years, and 44% are female. 212 (60.6%) patients are severe cases. Azvudine is used in 106 (30.2%) patients and not in 245 (69.8%). 72 patients died during hospitalization. After multivariate adjustment, patients who received Azvudine a lower risk of all-cause death (hazard ratio: 0.431; 95% confidence interval: 0.252-0.738; p = 0.002) than controls. Azvudine therapy is also associated with lower risks of shock and acute kidney injury. For sensitivity analysis in the propensity score-matched cohort (n = 90 for each group), there is also a significant difference in all-cause death between the two groups (hazard ratio: 0.189; 95% confidence interval: 0.071-0.498; p < 0.001). This study indicated that Azvudine therapy is associated with better outcomes in COVID-19 patients with pre-existing cardiovascular diseases.
Supporting Information Supporting Information is available from the Wiley Online Library or from the author. Conflict of Interest The authors declare no conflict of interest. Author Contributions
References
Deng, Li, Sun, Jin, Zhou et al., None, J. Med. Virol
Dian, Meng, Sun, Deng, Zeng, None, J Infect
Huang, Fei, Li, Xu, Xie et al., None, Int J Infect Dis
Huang, Wang, Li, Ren, Zhao et al., None, Lancet
Nhco, New coronavirus pneumonia prevention and control program
Ren, Luo, Yu, Song, Liang et al., None, Adv. Sci. (Weinh)
Sun, Jin, Dian, Shen, Zeng et al., None, EClini-calMedicine
Wenham, None, BMJ Clin. Res. Ed
Wise, None, BMJ Clin. Res. Ed
Yang, Wang, None, Eur. J. Med. Chem
Yu, Chang, None, Innovation (Camb)
Yu, Chang, None, Signal Transduct Target Ther
Zarocostas, None, Lancet
Zhang, Li, Wang, Liu, Lu et al., None, Signal. Transduct. Target. Ther
Zhang, Wang, Zhang, Zhou, Deng et al., None, Glob. Health Med
DOI record: { "DOI": "10.1002/advs.202306050", "ISSN": [ "2198-3844", "2198-3844" ], "URL": "http://dx.doi.org/10.1002/advs.202306050", "abstract": "<jats:title>Abstract</jats:title><jats:p>COVID‐19 can lead to adverse outcomes in patients with pre‐existing diseases. Azvudine has been approved for treating COVID‐19 in China, but the real‐world data is limited. It is aimed to investigate the efficacy of Azvudine in patients with COVID‐19 and pre‐existing cardiovascular diseases. Patients with confirmed COVID‐19 and pre‐existing cardiovascular diseases are retrospectively enrolled. The primary outcome is all‐cause death during hospitalization. Overall, 351 patients are included, with a median age of 74 years, and 44% are female. 212 (60.6%) patients are severe cases. Azvudine is used in 106 (30.2%) patients and not in 245 (69.8%). 72 patients died during hospitalization. After multivariate adjustment, patients who received Azvudine a lower risk of all‐cause death (hazard ratio: 0.431; 95% confidence interval: 0.252–0.738; <jats:italic>p</jats:italic> = 0.002) than controls. Azvudine therapy is also associated with lower risks of shock and acute kidney injury. For sensitivity analysis in the propensity score‐matched cohort (<jats:italic>n</jats:italic> = 90 for each group), there is also a significant difference in all‐cause death between the two groups (hazard ratio: 0.189; 95% confidence interval: 0.071–0.498; <jats:italic>p</jats:italic> &lt; 0.001). This study indicated that Azvudine therapy is associated with better outcomes in COVID‐19 patients with pre‐existing cardiovascular diseases.</jats:p>", "alternative-id": [ "10.1002/advs.202306050" ], "assertion": [ { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Received", "name": "received", "order": 0, "value": "2023-08-25" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Published", "name": "published", "order": 2, "value": "2024-03-27" } ], "author": [ { "affiliation": [ { "name": "Department of Cardiology, The Central Hospital of Wuhan, Tongji Medical College Huazhong University of Science and Technology Wuhan 430014 China" } ], "family": "Wu", "given": "Liu", "sequence": "first" }, { "affiliation": [ { "name": "Department of Cardiology, The Central Hospital of Wuhan, Tongji Medical College Huazhong University of Science and Technology Wuhan 430014 China" } ], "family": "He", "given": "Zhong‐Han", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Cardiology, The Central Hospital of Wuhan, Tongji Medical College Huazhong University of Science and Technology Wuhan 430014 China" } ], "family": "Huang", "given": "Ling", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Cardiology, The Central Hospital of Wuhan, Tongji Medical College Huazhong University of Science and Technology Wuhan 430014 China" } ], "family": "Guo", "given": "Xin", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Cardiology, The Central Hospital of Wuhan, Tongji Medical College Huazhong University of Science and Technology Wuhan 430014 China" } ], "family": "Li", "given": "Xu‐Yong", "sequence": "additional" }, { "affiliation": [ { "name": "State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases Chinese Academy of Medical Sciences &amp; Peking Union Medical College Beijing 100037 China" } ], "family": "Zhang", "given": "Hong‐Da", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Cardiology, The Central Hospital of Wuhan, Tongji Medical College Huazhong University of Science and Technology Wuhan 430014 China" } ], "family": "Chen", "given": "Man‐Hua", "sequence": "additional" } ], "container-title": "Advanced Science", "container-title-short": "Advanced Science", "content-domain": { "crossmark-restriction": true, "domain": [ "onlinelibrary.wiley.com" ] }, "created": { "date-parts": [ [ 2024, 3, 28 ] ], "date-time": "2024-03-28T05:40:33Z", "timestamp": 1711604433000 }, "deposited": { "date-parts": [ [ 2024, 3, 28 ] ], "date-time": "2024-03-28T05:40:41Z", "timestamp": 1711604441000 }, "funder": [ { "DOI": "10.13039/501100001809", "award": [ "82000064;81900334" ], "doi-asserted-by": "publisher", "name": "National Natural Science Foundation of China" } ], "indexed": { "date-parts": [ [ 2024, 3, 29 ] ], "date-time": "2024-03-29T01:18:17Z", "timestamp": 1711675097807 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2024, 3, 27 ] ] }, "language": "en", "license": [ { "URL": "http://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 3, 27 ] ], "date-time": "2024-03-27T00:00:00Z", "timestamp": 1711497600000 } } ], "link": [ { "URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/advs.202306050", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "311", "original-title": [], "prefix": "10.1002", "published": { "date-parts": [ [ 2024, 3, 27 ] ] }, "published-online": { "date-parts": [ [ 2024, 3, 27 ] ] }, "publisher": "Wiley", "reference": [ { "DOI": "10.1016/S0140-6736(20)30183-5", "doi-asserted-by": "publisher", "key": "e_1_2_10_1_1" }, { "DOI": "10.1016/S0140-6736(23)01003-6", "doi-asserted-by": "publisher", "key": "e_1_2_10_2_1" }, { "author": "Wenham C.", "journal-title": "BMJ Clin. Res. Ed.", "key": "e_1_2_10_3_1", "volume": "381", "year": "2023" }, { "DOI": "10.1136/bmj.p1041", "doi-asserted-by": "publisher", "key": "e_1_2_10_4_1" }, { "DOI": "10.35772/ghm.2022.01063", "doi-asserted-by": "publisher", "key": "e_1_2_10_5_1" }, { "key": "e_1_2_10_6_1", "unstructured": "Prevention CCFDCa The National COVID‐19 Infection Status.https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202306/t20230611_266656.htm.2023. June." }, { "DOI": "10.1016/j.ejmech.2023.115503", "doi-asserted-by": "publisher", "key": "e_1_2_10_7_1" }, { "DOI": "10.1002/advs.202001435", "doi-asserted-by": "publisher", "key": "e_1_2_10_8_1" }, { "DOI": "10.1038/s41392-021-00835-6", "doi-asserted-by": "publisher", "key": "e_1_2_10_9_1" }, { "DOI": "10.1002/jmv.28756", "doi-asserted-by": "publisher", "key": "e_1_2_10_10_1" }, { "DOI": "10.1016/j.eclinm.2023.101981", "doi-asserted-by": "publisher", "key": "e_1_2_10_11_1" }, { "key": "e_1_2_10_12_1", "unstructured": "China NHCo New coronavirus pneumonia prevention and control program (the tenth edition).http://www.nhc.gov.cn/xcs/zhengcwj/202301/bdc1ff75feb94934ae1dade176d30936.shtml.2023. January." }, { "DOI": "10.1038/s41392-020-00351-z", "doi-asserted-by": "publisher", "key": "e_1_2_10_13_1" }, { "DOI": "10.1016/j.xinn.2022.100321", "doi-asserted-by": "publisher", "key": "e_1_2_10_14_1" }, { "author": "Dian Y.", "first-page": "27", "journal-title": "J Infect.", "key": "e_1_2_10_15_1", "volume": "24", "year": "2023" }, { "DOI": "10.1016/j.ijid.2021.01.009", "doi-asserted-by": "publisher", "key": "e_1_2_10_16_1" }, { "DOI": "10.1016/S0140-6736(22)00101-5", "doi-asserted-by": "publisher", "key": "e_1_2_10_17_1" } ], "reference-count": 17, "references-count": 17, "relation": {}, "resource": { "primary": { "URL": "https://onlinelibrary.wiley.com/doi/10.1002/advs.202306050" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "General Physics and Astronomy", "General Engineering", "Biochemistry, Genetics and Molecular Biology (miscellaneous)", "General Materials Science", "General Chemical Engineering", "Medicine (miscellaneous)" ], "subtitle": [], "title": "Azvudine for the Treatment of COVID‐19 in Pre‐Existing Cardiovascular Diseases: A Single‐Center, Real‐World Experience", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1002/crossmark_policy" }
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit